Patent intelligence · US
US 10273307
Humanized anti-CD134 (OX40) antibodies and uses thereof
Humanized anti-CD134 (OX40) antibodies and uses thereof
Patent details — US 10273307
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 30, 2019
- Expiration
- Apr 25, 2039
- Applicant
- Biocerox Products B.V.
- Claims
- 17
- CPC classes
- A61P, A61P35/00, A61P37/04
Quick answer
US 10273307 (Humanized anti-CD134 (OX40) antibodies and uses thereof) is held by Biocerox Products B.V.. Status: granted. Granted Apr 30, 2019. Expires Apr 25, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Biocerox Products B.V.
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61P, A61P35/00, A61P37/04
More from Biocerox Products B.V.
Related pharmaceutical patents in our USPTO index.
-
US 12303551
Cellular immunotherapy compositions and uses thereof
granted -
US 12291557
Chimeric TIM4 receptors and uses thereof
granted -
US 11708423
Chimeric engulfment receptor molecules and methods of use
granted -
US 11697689
Use of antibody against O-acetylated GD2 ganglioside to improve the therapeutic potential of drugs
granted -
US 11655282
Chimeric engulfment receptor molecules
granted -
US 10675246
Orally administrable compositions comprising calcium
granted -
US 10307410
Mcl-1 modulating compounds for cancer treatment
granted
Frequently asked questions
What is US patent 10273307?
US 10273307 (Humanized anti-CD134 (OX40) antibodies and uses thereof) is held by Biocerox Products B.V.. Status: granted. Granted Apr 30, 2019. Expires Apr 25, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10273307?
Biocerox Products B.V. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 14 pharmaceutical patents for this assignee.
When does US 10273307 expire?
Our index shows an expiration date of Apr 25, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.